Opinion

Video

Limitations of Conventional Imaging for Assessing Renal Masses

Experts on kidney cancer review challenges associated with limitations of conventional imaging for assessing renal masses and how to potentially improve sensitivity and specificity.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      1 expert in this video
      BPH: The Patient Journey
      Addressing Remaining Unmet Needs in mCRPC
      Addressing Remaining Unmet Needs in mCRPC
      Use and Sequencing of Novel Treatments in NMIBC
      Use and Sequencing of Novel Treatments in NMIBC
      The DORA Trial
      The DORA Trial
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      FDA-Approved Treatments for BCG-Unresponsive NMIBC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC
      Clinical Perspectives on Early Use of RAD-ENZ
      Clinical Perspectives on Early Use of RAD-ENZ
      Treatment Selection for mCRPC
      Treatment Selection for mCRPC
      Other Investigational Drug Delivery Systems in NMIBC
      Other Investigational Drug Delivery Systems in NMIBC
      Related Content
      Subcutaneous nivolumab under review in EU for solid tumors
      March 31st 2025

      Subcutaneous nivolumab under review in EU for solid tumors

      Hannah Clarke
      The European Commission must issue a decision on the application on or by June 2, 2025.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      FDA greenlights trial of orellanine in metastatic renal cell carcinoma
      March 18th 2025

      FDA greenlights trial of orellanine in metastatic renal cell carcinoma

      Hannah Clarke
      The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      FDA updates in urology: February 2025
      March 3rd 2025

      FDA updates in urology: February 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from February 2025.
      Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
      February 26th 2025

      Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma

      Camillo Porta, MD
      "At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
      © 2025 MJH Life Sciences

      All rights reserved.